KPV side effects

What is known in people

• Studies: no person is known to have received KPV in a study.¹ FDA looked in two literature databases, the US trial registry and its own adverse event systems and found no record of human use by any route.¹ The trial registry still listed no KPV study in October 2026.²
• Reports: FDA's adverse event database (FAERS) held no KPV reports through December 3, 2025.¹
• FDA's position: its compounding list, current as of April 22, 2026, says FDA lacks important information on whether KPV would cause harm if given to people.³

Possible risks, most serious first

None of these risks has a measured frequency for KPV. They are the hazards regulators and reviewers name for KPV or for products like it.

Organ damage, blood clots and tumor growth (class warning)

Health Canada's April 2026 advisory on unauthorized injectable peptides lists liver or kidney damage, blood clots and the growth of cancerous tumors among the risks of these products, and it names KPV among the peptides it has seized.⁴ These warnings cover the whole group of products; they are not effects measured for KPV.⁴

Immune reactions

FDA warns that peptides such as KPV can trigger an immune response (immunogenicity), with outcomes from no symptoms to life-threatening reactions.¹ Aggregation, the clumping of peptide molecules, adds to the risk, and FDA says the data are too thin to conclude KPV is free of it.¹ FDA says it is particularly concerned about the lack of any human data for any route, including data to assess immune reactions or clumping.¹

Getting the wrong or an untested substance

KPV is a common name, not an official drug name, and FDA has seen several salts and derivatives, some with a different active part, sold under it.¹ FDA treats this as a safety risk because a person may get a different substance than intended.¹ Most published certificates of analysis for KPV free base that FDA found reported only purity, with no impurity limits or aggregation data; FDA found no microbiological test data for either form and judged both KPV free base and KPV acetate not well characterized.¹ A 2026 review of peptides in sport adds that the largely unregulated supply leaves products often mislabeled or contaminated.⁵

Skin darkening: not reported

KPV is the last three amino acids of alpha-MSH, the hormone that darkens skin, but a 2019 review reports that it lacks the hormone's pigment-inducing activity.⁶ In cell tests it did not compete for binding at the MC1 receptor, through which alpha-MSH acts on pigment cells.⁷ These are lab and animal findings; no human study has checked.¹

What has not been studied

• Toxicity in animals: FDA found no acute or repeat-dose toxicity, genotoxicity, developmental and reproductive toxicity, or carcinogenicity studies of KPV.¹
• Pregnancy and breastfeeding: with no human data and no reproductive studies in animals, the risk is unknown.¹
• Long-term use: FDA found no repeat-dose data in people or animals, so the effects of using KPV over weeks or months are unknown.¹
• Absorption: FDA found no human pharmacokinetic data, so how much KPV reaches the blood by any route is unknown.¹
• Skin products: KPV did not cross intact human skin in detectable amounts in a lab test, while microneedles and a weak electric current (iontophoresis) raised delivery sharply.⁸ FDA notes it is unknown whether such methods also raise absorption into the body.¹

Why no reports does not mean no harm

FAERS relies on voluntary reports, and FDA notes that pharmacies compounding under section 503A generally do not report adverse events.¹ With no human studies and no tracked use, an empty record says that harm has not been measured, not that it is absent.¹

Warnings

• Regulators: Health Canada warns consumers not to use unauthorized peptide drugs such as KPV, and says research-use-only labels do not make them legal or exempt from its rules.⁴
• Athletes: USADA says the 2027 WADA Prohibited List, in force from January 1, 2027, names peptides in general as prohibited substances in class S0, which covers substances not approved for human use.⁹
• Research use: vials sold here carry the label: For research use only. Not for human or veterinary use.

General precautions are in Peptide safety basics.

Related pages

Back to the KPV profile. The cell and animal findings are in KPV benefits and uses, and the amounts used in studies are in KPV dosage. For a blend that includes KPV, see KLOW Peptide Blend side effects. For the vial's specifications and storage figures, see KPV for sale.